Drucker Wealth 3.0 LLC Decreases Stake in IQVIA Holdings Inc. $IQV

Key Points

• Drucker Wealth 3.0 LLC reduced its stake in IQVIA Holdings Inc. by 44.2%, owning 2,804 shares valued at approximately $454,000, after selling 2,223 shares in the second quarter.
• Analysts have set a new price target for IQVIA, with Evercore ISI raising it to $240.00 and several other firms maintaining or upgrading their ratings, indicating strong market confidence with an average target of $236.45.
• During the second quarter, insiders sold significant shares, including Eric Sherbet, who sold 5,800 shares for over $1.1 million, reflecting a noteworthy decrease in their ownership positions.

Drucker Wealth 3.0 LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 44.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,804 shares of the medical research company's stock after selling 2,223 shares during the quarter. Drucker Wealth 3.0 LLC's holdings in IQVIA were worth $454,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd raised its holdings in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth approximately $33,000. Larson Financial Group LLC raised its holdings in IQVIA by 109.9% during the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock worth $48,000 after purchasing an additional 144 shares in the last quarter. Finally, Atticus Wealth Management LLC acquired a new stake in IQVIA during the second quarter worth approximately $52,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the topic of a number of research analyst reports. Evercore ISI raised their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an "outperform" rating in a report on Wednesday. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Hsbc Global Res raised shares of IQVIA from a "hold" rating to a "strong-buy" rating in a report on Thursday. Finally, Barclays lifted their target price on shares of IQVIA from $185.00 to $200.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $236.45.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Performance

NYSE:IQV opened at $198.35 on Friday. The firm's fifty day moving average price is $189.02 and its 200 day moving average price is $168.19. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $33.72 billion, a price-to-earnings ratio of 28.70, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the firm posted $2.64 EPS. IQVIA's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.